This new analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type chronic lymphocytic leukemia. The findings fill a meaningful gap for the authors, who ...
New data presented at EHA 2026 showed durable long-term outcomes for BRUKINSA in patients aged 80 and older, while additional ...
A phase 3, randomized, open-label trial enrolled 535 patients who were randomly assigned 1:1:1 to receive acalabrutinib-obinutuzumab (n = 179), acalabrutinib monotherapy (n = 179), or ...
Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...
Aging and CLL amplify fatigue, anemia, and infection risks, impacting physical activity and recovery. Tailored strategies, such as anti-inflammatory diets and strength training, can enhance resilience ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results